Ontology highlight
ABSTRACT:
SUBMITTER: Villaruz LC
PROVIDER: S-EPMC4844000 | biostudies-literature | 2016 Mar
REPOSITORIES: biostudies-literature
Villaruz Liza C LC Socinski Mark A MA
European journal of cancer (Oxford, England : 1990) 20160212
Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European Commission in 2015. This approval was based on the results of a phase III clinical trial showing superior response rates compared with solvent-based paclitaxel in combination with carboplatin. This re ...[more]